21 CFR Part 211 · Current Good Manufacturing Practice for Finished Pharmaceuticals

21 CFR 211.137

Expiration dating

21 CFR 211.137 is the regulation titled “Expiration dating” in 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. Since 2021, 28 FDA warning letters have cited it.

Letters citing it
28 since 2021
Jan 1 to Oct 30, 2026
4 against 6 on the same dates in 2025
Most often cited with
21 CFR 211.165, in 23 letters
Closed out
0% of these letters have a published close-out
See the 28 letters citing 21 CFR 211.137 →

Letters citing it, by year issued

All are drug letters. 2026 runs to Oct 30, 2026. Pick a year to see its letters.

  1. 22021
  2. 22022
  3. 32023
  4. 102024
  5. 72025
  6. 42026

What FDA writes when it cites it

The finding headings that cite 21 CFR 211.137 most often, as written in the letters.

  • 13 lettersYour firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a))

The regulation

Read the text of 21 CFR 211.137 (eCFR, as of Sep 1, 2026)

(a) To assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use, it shall bear an expiration date determined by appropriate stability testing described in § 211.166.

(b) Expiration dates shall be related to any storage conditions stated on the labeling, as determined by stability studies described in § 211.166.

(c) If the drug product is to be reconstituted at the time of dispensing, its labeling shall bear expiration information for both the reconstituted and unreconstituted drug products.

(d) Expiration dates shall appear on labeling in accordance with the requirements of § 201.17 of this chapter.

(e) Homeopathic drug products shall be exempt from the requirements of this section.

(f) Allergenic extracts that are labeled “No U.S. Standard of Potency” are exempt from the requirements of this section.

(g) New drug products for investigational use are exempt from the requirements of this section, provided that they meet appropriate standards or specifications as demonstrated by stability studies during their use in clinical investigations. Where new drug products for investigational use are to be reconstituted at the time of dispensing, their labeling shall bear expiration information for the reconstituted drug product.

(h) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this section shall not be enforced for human OTC drug products if their labeling does not bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability data.

[43 FR 45077, Sept. 29, 1978, as amended at 46 FR 56412, Nov. 17, 1981; 60 FR 4091, Jan. 20, 1995]

Text from eCFR as of Sep 1, 2026.

Cited alongside it

Regulations that appear in the same letters as 21 CFR 211.137.

Latest letters citing it

The 3 letters citing 21 CFR 211.137 that FDA posted most recently.

See the 28 letters citing 21 CFR 211.137 →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Counts include every citation in a letter, as the Letters filter does. How this database is built.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.